Canadian clinical practice guidelines for acute and chronic rhinosinusitis

Table 6 Studies Investigating Alternative Therapy Duration, Dose, or Formulation

Agent	Comparator	Success Rate	Side Effects
*Duration*
Azithromycin [96]	Amoxicillin/clavulanate	88.8% and 84.9%, vs 84.9%	Higher for amox/clav group
500 mg/d	1500/375 mg/d
3 or 6 days	10 days
Azithromycin [95] microspheres	Levofloxacin	92.5% vs 92.8%	Comparable
2 g	500 mg/d
1 day	10 days
Azithromycin [97] (meta-analysis)	Amoxicillin, roxithromycin, cefaclor, erythromycin, amoxicillin/clavulanate, clarithromycin, penicillin	Comparable	Comparable
3 or 5 days
Levofloxacin [98]	Levofloxacin	>90% for both groups	Comparable
750 mg/d	500 mg/d
5 days	10 days
Gatifloxacin [99]*	Amoxicillin/clavulanate	74% and 80%, vs 72%	Comparable
400 mg/d	1750/250 mg/d
5 or 10 days	10 days
Gemifloxacin [100]	Gemifloxacin	83.5% vs 84.2%	Comparable
320 mg/d	320 mg/d
5 days	7 days
*Dosing*
Amoxicillin/clavulanate [101]	Amoxicillin/clavulanate	88% vs 93%	Comparable
500/125 mg	875/125 mg
Every 8 hours	Every 12 hours
*Formulation*
Clarithromycin [102] ER	Amoxicillin/clavulanate	98% vs 97%	Comparable
1000 mg/d	1750/250 mg/d
14 days	14 days

*The fluoroquinolone, gatifloxacin was removed from the market following a study demonstrating potentially life-threatening glycemic events [103].
ER, extended release.

ISSN: 1710-1492